SS  Vol.3 No.2 , February 2012
Peritoneal Colorectal Carcinomatosis Treated with Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy
Background-Aims: Peritoneal colorectal carcinomatosis is a potentially curative disease. The purpose of the study is the retrospective analysis of survival of the patients with peritoneal colorectal carcinomatosis that underwent cytoreductive surgery and perioperative intraperitoneal chemotherapy and the identification of prognostic variables of the disease. Patients-Methods: Patients with primary or recurrent colorectal cancer and peritoneal carcinomatosis were included in the study. Clinical variables were correlated to survival, recurrence, hospital mortality, and morbidity. Results: From 2000-2010, 28 patients underwent 33 cytoreductive operations. The hospital mortality and morbidity rate was 9.1% and 45.5% respectively. The overall 5-year and median survival time was 29.2% and 19 months respectively. The extent of peritoneal carcinomatosis (p = 0.0003) and the completeness of cytoreduction (p = 0.0002) were related to survival. The completeness of cytoreduction (p = 0.003) was the single prognostic variable of survival. The recurrence rate was 42.4% and the use of systemic chemotherapy was identified as the single prognostic variable of recurrence (p = 0.047). Conclusions: Patients with limited extent of peritoneal colorectal carcinomatosis who undergo complete cytoreduction may be offered long-term survival.

Cite this paper
A. Tentes, O. Korakianitis, N. Pallas, C. Mavroudis, P. Sarlis, A. Liberis, A. Pagalos and S. Popidis, "Peritoneal Colorectal Carcinomatosis Treated with Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy," Surgical Science, Vol. 3 No. 2, 2012, pp. 72-77. doi: 10.4236/ss.2012.32013.

[1]   D. G. Jayne, S. Fook, C. Loi and F. Seow-Choen, “Peritoneal Carcinomatosis from Colorectal Cancer,” British Journal of Surgery, Vol. 89, No. 12, 2002, pp. 1545-1550. doi:10.1046/j.1365-2168.2002.02274.x

[2]   P. H. Sugarbaker, “Intraperitoneal Chemotherapy and Cytoreductive Surgery for the Prevention and Treatment of Peritoneal Carcinomatosis and Sarcomatosis,” Seminars in Surgical Oncology, Vol. 14, No. 3, 1998, pp. 254-261. doi:10.1002/(SICI)1098-2388(199804/05)14:3<254::AID-SSU10>3.0.CO;2-U

[3]   P. H. Sugarbaker, “Management of Peritoneal-Surface malignancy: The Surgeon’s Role,” Langenbeck’s Archives of Surgery, Vol. 384, No. 6, 1999, pp. 576-587. doi:10.1007/s004230050246

[4]   P. H. Sugarbaker, W. Cuniffe, J. F. Belliveau, E. de Bruin and T. Graves, “Rationale for Perioperative Intraperitoneal Chemotherapy as a Surgical Adjuvant for Gastrointestinal Malignancy,” Regional Cancer Treatment, Vol. 1, 1988, pp. 66-79.

[5]   D. Elias and J. F. Ouellet, “Intraperitoneal Chemohyperthermia. Rationale, Technique, Indications, and Results,” Surgical Oncology Clinics of North America, Vol. 10, No. 4, 2001, pp. 915-933.

[6]   National Institute for Health and Clinical Excellence, “Cytoreduction Surgery Followed by Hyperthermic Intraoperative Peritoneal Chemotherapy for Peritoneal Carcinomatosis,” February 2010, ISBN 978-1-84936-174-3.

[7]   P. H. Sugarbaker, “Technical Handbook for the Integration of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy into the Surgical Management of Gastrointestinal and Gynaecologic Malignancy,” 4th Edition, Ludann Company, Grand Rapids, Michigan, 2005, pp. 12-24.

[8]   M. J. Koppe, O. C. Boerman, W. J. Oyen, et al., “Peritoneal Carcinomatosis of Colorectal Origin. Incidence and Current Treatment Strategies,” Annals of Surgery, Vol. 243, No. 2, 2006, pp. 212-222. doi:10.1097/01.sla.0000197702.46394.16

[9]   B. van Ooijen, M. van der Burg, A. Planting, P. Siersema and T. Wiggers, “Surgical Treatment of Gastric Drainage Only for Intestinal Obstruction in Patients with Carcinoma of the Ovary or Peritoneal Carcinomatosis of Other Origin,” Surgery, Gynecology & Obstetrics, Vol. 176, No. 5, 1993, pp. 469-474.

[10]   D. Elias, J. H. Lefevre, J. Chevalier, A. Brouquet, F. Marchal, J. M. Classe, G. Ferron, J. M. Guillot, D. Goere and J. Bonastre, “Complete Cytoreductive Surgery plus Intraperitoneal Chemohyperthermia with Oxaliplatin for Peritoneal Carcinomatosis of Colorectal Origin,” Journal of Clinical Oncology, Vol. 27, No. 5, 2009, pp. 681-685. doi:10.1200/JCO.2008.19.7160

[11]   H. Mahteme, J. Hansson, L. Pahlman, B. Glimelius, P. Nygren and W. Graf, “Improved Survival in Patients with Peritoneal Metastases from Colorectal Cancer: A Preliminary Study,” British Journal of Surgery, Vol. 90, No. 2, 2004, pp. 403-407. doi:10.1038/sj.bjc.6601586

[12]   D. Elias, F. N. Gilly, F. Boutitie, F. Quenet, J. M. Bereder, B. Mansvelt, G. Lorimier, P. Dube and O. Glehen, “Peritoneal Colorectal Carcinomatosis Treated with Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective Analysis of 523 Patients from Multicentric French Study,” Journal of Clinical Oncology, Vol. 28, No. 1, 2010, pp. 63-68. doi:10.1200/JCO.2009.23.9285

[13]   V. J. Verwaal, S. van Ruth, E. de Bree, G. W. van Slooten, H. van Tinteren, H. Boot and F. A. N. Zoetmulder, “Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy versus Systemic Chemotherapy and Palliative Surgery in Patients with Peritoneal Carcinomatosis of Colorectal Cancer,” Journal of Clinical Oncology, Vol. 21, No. 20, 2003, pp. 3737-3743. doi:10.1200/JCO.2003.04.187

[14]   V. J. Verwaal, S. Bruin, H. Boot, G. van Slooten and H. van Tinteren, “8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Chemotherapy versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer,” Annals of Surgical Oncology, Vol. 15, No. 9, 2008, pp. 2426-2432. doi:10.1245/s10434-008-9966-2

[15]   O. Glehen, F. N. Gilly, F. Boutitie, J. M. Bereder, F. Quenet, L. Sideris, B. Mansvelt, G. Lorimier, S. Msika and D. Elias, French Surgical Association, “Toward Curative Treatment of Peritoneal Carcinomatosis from Nonovarian Origin by Cytoreductive Surgery Combined with Perioperative Intraperitoneal Chemotherapy: A Multi-Institutional Study of 1290 Patients,” Cancer, Vol. 15, No. 24, 2010, pp. 5608-5618. doi:10.1002/cncr.25356

[16]   O. Glehen, F. Kwiatkowski, P. H. Sugarbaker, D. Elias, E. A. Levine, M. De Simone, R. Barone, Y. Yonemura, F. Cavaliere, F. Quenet, M. Gutman, A. A. Tentes, G. Lorimier, J. L. Bernard, J. M. Bereder, J. Porcheron, A. Gomez-Portilla, P. Shen, M. Deraco and P. Rat, “Cytoreductive Surgery Combined with Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal Carcinomatosis from Colorectal Cancer: A Multi-Institutional Study,” Journal of Clinical Oncology, Vol. 22, No. 16, 2004, pp. 3284-32

[17]   D. Elias, B. Raynard, V. Boige, A. Laplanche, G. Estphan, D. Malka and M. Pocard, “Impact of the Extent and Duration of Cytoreductive Surgery on Postoperative Haematological Toxicity after Intraperitoneal Chemohyperthermia for Peritoneal Carcinomatosis,” Journal of Surgical Oncology, Vol. 90, No. 4, 2005, pp. 220-225. doi:10.1002/jso.20253

[18]   D. Elias, D. Goere, F. Blot, V. Billard, M. Pocard, N. Kohneh-Shahri and B. Raynard, “Optimization of Hyperthermic Intraperitoneal Chemotherapy with Noxiplatin plus Irrinotecan at 43?C after Complete Cytoreductive Surgery: Mortality and Morbidity in 106 Consecutive Patients,” Annals of Surgical Oncology, Vol. 14, No. 6, 2007, pp. 1818-1824. doi:10.1245/s10434-007-9348-1

[19]   F. Cavaliere, M. De Simone, S. Virzi, M. Deraco, C. R. Rossi, A. Garofalo, F. Di Filippo, D. Giannarelli, M. Vaira, M. Valle, P. Pilati, P. Perri, M. La Pinta, I. Monsellato and F. Guadagni, “Prognostic Factors and Oncologic Outcome in 146 Patients with Colorectal Peritoneal Carcinomatosis Treated with Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy: Italian Multicenter Study, SITILO,” European Journal of Surgical Oncology, Vol. 37, No. 2, 2011, pp. 148-154.

[20]   P. Sugarbaker and K. Jablonski, “Prognostic Features of 51 Colorectal and 130 Appendiceal Cancer Patients with Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy,” Annals of Surgery, Vol. 221, No. 2, 1995, pp. 124-132. doi:10.1097/00000658-199502000-00002